Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT

NCT07675174 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

GVHD - Graft-Versus-Host Disease

Interventions

DRUG: Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD

Sponsor

Northwell Health